CVE-2004-2030

Description

Multiple cross-site scripting (XSS) vulnerabilities in index.jsp for Liferay before 2.2.0 release 10/1/2004 allow remote attackers to inject arbitrary web script or HTML, as demonstrated using the message subject.

Category

4.3
CVSS
Severity: Medium
CVSS 2.0 •
EPSS 1.62% Top 20%
Vendor Advisory secunia.com Vendor Advisory osvdb.org Vendor Advisory securityfocus.com
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
http://marc.info/?l=bugtraq&m=110141194202856&w=2 mailing list
http://securitytracker.com/id?1010259 vdb entry
http://secunia.com/advisories/11692 third party advisory vendor advisory
http://www.osvdb.org/6346 vdb entry patch vendor advisory
http://sourceforge.net/project/shownotes.php?release_id=252060
http://www.securityfocus.com/bid/10402 vdb entry patch vendor advisory
https://exchange.xforce.ibmcloud.com/vulnerabilities/16232 vdb entry
http://marc.info/?l=bugtraq&m=108526683823840&w=2 mailing list

Frequently Asked Questions

What is the severity of CVE-2004-2030?
CVE-2004-2030 has been scored as a medium severity vulnerability.
How to fix CVE-2004-2030?
To fix CVE-2004-2030, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2004-2030 being actively exploited in the wild?
It is possible that CVE-2004-2030 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~2% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.